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Abstract
Current egg-based influenza vaccine production technology can’t promptly meet the global demand during an influenza
pandemic as shown in the 2009 H1N1 pandemic. Moreover, its manufacturing capacity would be vulnerable during
pandemics caused by highly pathogenic avian influenza viruses. Therefore, vaccine production using mammalian cell
technology is becoming attractive. Current influenza H5N1 vaccine strain (NIBRG-14), a reassortant virus between A/
Vietnam/1194/2004 (H5N1) virus and egg-adapted high-growth A/PR/8/1934 virus, could grow efficiently in eggs and MDCK
cells but not Vero cells which is the most popular cell line for manufacturing human vaccines. After serial passages and
plaque purifications of the NIBRG-14 vaccine virus in Vero cells, one high-growth virus strain (Vero-15) was generated and
can grow over 10
8 TCID50/ml. In conclusion, one high-growth H5N1 vaccine virus was generated in Vero cells, which can be
used to manufacture influenza H5N1 vaccines and prepare reassortant vaccine viruses for other influenza A subtypes.
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Introduction
Outbreaks of avian influenza H5N1 viruses emerged in 1997
and are still killing avian hosts and causing zoonotic transmission
to humans in 2011, posing the persistent threat of influenza
pandemics in humans [1]. Vaccination is the most cost-effective
strategy to control and prevent influenza pandemics and seasonal
epidemics. Most current seasonal influenza vaccines are manu-
factured using chicken embryonated eggs, which is labor-intensive
and hard to scale up during a pandemic. Moreover, egg supply
may not be available during a pandemic causing by H5N1 viruses
that are highly pathogenic to chickens. Therefore, the World
Health Organization (WHO) has been encouraging the develop-
ment of cell-based influenza H5N1 vaccines since 2006 [2].
Two cell lines, Vero and MDCK cells, have been licensed for
manufacturing influenza vaccines [3,4,5,6]. In addition to influenza
vaccines, Vero cells have been widely approved for manufacturing
other human vaccines but MDCK cells are only licensed for
influenza vaccines. Currently, there are four clades of influenza
H5N1 viruses circulating in avian hosts and causing zoonotic
transmission to humans. Therefore, the WHO have collaborated
with reference labs to prepare vaccine seed viruses from repre-
sentative viruses of the two clades for vaccine development and
production [1]. The current clade-1 influenza H5N1 vaccine strain
(NIBRG-14), provided from the UK NIBSC (National Institute for
Biological Standards and Control), is a reassortant virus containing
NA and modified HA gene segments of A/Vietnam/1194/2004
(H5N1) virus and the other 6 gene segments of egg-adapted high-
growth A/PR/8/1934 (H1N1) virus [7]. The NIBRG-14 vaccine
virus could grow to high titers in chicken eggs and MDCK cells but
not Vero cells which is the most popular cell line for manufacturing
human vaccines [8,9,10,11]. Historical studies have shown that
high-growth influenza viruses can be selected through continuous
passages and plaque purifications in eggs and cells [12,13]. This
study was conducted to adapt the NIBRG-14 vaccine virus to grow
efficiently in Vero cells.
Results
Growth curve of NIBRG-14 and Vero-adapted viruses
The NIBRG-14 viruses could only form small and ambiguous
plaques after 6 days post infection in Vero cells (Figure 1) and
reach peak infectious virus titers about 10
5.5 TCID50/ml (Table 1).
After three passages, several big plaques were observed so a plaque
purification was conducted at the fourth passage. Another plaque
purification was conducted at the sixth passage. Overall, after 11
passages including 2 times of plaque purifications in Vero cells,
one high-growth virus clone (Vero-15) was selected. The Vero-15
virus can form clear and big plaques after 3 days post infection in
Vero cells (Figure 1) and reach peak infectious virus titers about
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8 TCID50/ml (Table 1). The Vero-15 virus was further used to
produce virus stocks in T-flasks with high virus titers (1.9610
8
TCID50/ml and 1.4610
8 PFU/ml) for further evaluations
including genetic and antigenic characterization and pilot produc-
tion in microcarrier-based cell cultures.
Antigenic and genetic characterization
Using the NIBRG-14 standard sheep antisera, HI antibody
titers against the NIBRG-14 and Vero-15 viruses were 800 and
400, respectively. The results indicate these two viruses have
similar antigenicity. Compared with the NIBRG-14 strain, the
Vero-15 strain does not have any nucleotide difference in HA,
NA, NP and M gene segments but has 1–4 nucleotide differences
in PB2, PB1, PA and NS gene segments (Table 2). The only amino
acid change in PB2 protein between the NIBRG-14 and Vero-15
viruses was SRY at position 360 (based on PR8 numbering),
which is not likely related to the well-defined marker of
pathogenicity at position 627 [14].
Virus growth in microcarriers
Using 5 g/L of microcarriers and serum-containing medium in
100-ml scale spinner flasks, cells grew to confluence (,2610
6
cells/ml) at day 4 or 5. After infected with the Vero-15 viruses
under MOI of 0.0001, infectious virus titers sharply increased at
day 3 and peaked at day 5 (10
8.78 TCID50/ml). The HA titers had
the similar pattern (Table 3).
Discussion
It is well known that wild-type influenza viruses and egg-
adapted high-growth reasortant influenza vaccine viruses can grow
efficiently in MDCK cells but not Vero cells [3,15–18]. After 20
passages of an egg-adaptedd high-growth reassortant H1N1
vaccine virus in Vero cells, the titer of infectious virus increased
3 (7.18 to 7.70 log10 PFU/ml) to 26 (6.95 to 8.37 log10 TCID50/
ml) folds and their viral antigenicity and HA sequences were stable
in a previous study [15]. In our study, we adapted an egg-based
high-growth reassortant H5N1 vaccine virus after 11 passages in
Vero cells including 2 times of plaque purification. Our Vero cell-
adapted H5N1 virus increased over 100 folds in infectious virus
titers measured by TCID50 and plaque assay without changing
antigenicity and HA sequences.
Based on statistics from the WHO in March 2008, more than
70 clinical trials of pandemic influenza vaccines have been
completed or are ongoing (www.who.int). Since most vaccine
manufacturers used the egg-based technology for production of
seasonal influenza vaccines and converted the egg-based facility to
manufacture influenza H5N1 vaccines for clinical trials, only 6
clinical trials used cell-based vaccines. Most of the 6 trials using
Figure 1. Plaque morphology of NIBRG-14 and Vero cell-adapted (Vero-15) H5N1 viruses grown in Vero cells in different days post
infection (DPI).
doi:10.1371/journal.pone.0024057.g001
Table 1. Growth efficiency of the NIBRG-14 and Vero-adapted influenza H5N1 (Vero-15) viruses with different multiplicity of
infection (MOI) in T-flasks.
NIBRG-14 (MOI=10
22) NIBRG-14 (MOI=10
23) Vero-15 (MOI=10
23) Vero-15 (MOI=10
24)
Days post-infection TCID50/ml (log10) TCID50/ml (log10) TCID50/ml (log10) TCID50/ml (log10)
1 ,2 ,2 4.3360.07 3.7160.10
2 ,2 ,2 6.8060.17 7.8060.24
3 4.1660.13 4.9360.29 7.03±0.23 8.30±0.13
4 4.4260.07 4.7860.52 not available not available
5 4.55±0.13 5.53±0.03 not available not available
TCID50 (50% tissue culture infectious dose) was measured in triplicate and shown as geometric mean 6 standard error of mean.
Boldfaces indicate peak infectious virus titers.
doi:10.1371/journal.pone.0024057.t001
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based on Vero cells. As the NIBRG-14 virus can not grow
efficiently in Vero cells, wild-type A/Vietnam/1203/2004 (H5N1)
was used to manufacture vaccines in Vero cells in facility under
biosafety level 3 [10], which is not feasible in most developing
countries. In our study, a high-growth H5N1 virus was generated
in Vero cells. Ideally, antigenicity of influenza vaccine strains
should be tested using ferret antisera, which are not readily
available. Alternatively, we used the NIBSC sheep standard
antisera to perform the antigenicity test. Moreover, the Vero-
adapted H5N1 virus has the same HA sequence with the NIBRG-
14 virus, which further indicated the same antigenicity between
the Vero-adated H5N1 and NIBRG-14 viruses. We further
demonstrated commercial potential of the Vero-adapted H5N1
virus in the microcarrier-based cell culture system reaching peak
virus at 10
10 TCID50/ml which is higher than that of the NIBRG-
14 virus in microcarrier-based MDCK cell cultures (10
8–9
TCID50/ml) [9]. Scale-up production and process development
in the microcarrier-based Vero cell culture system are ongoing.
In addition to being used as the seed virus for manufacturing
H5N1 vaccines, the Vero-adapted virus has the potential to
become a master virus to generate high-growth reassortants for
other influenz A viruses. The current egg-based technology for
vaccine production is heavily relied on the high-growth PR8
master virus for generating seed viruses [12]. Therefore, it would
be desirable to establish high-growth master viruses for Vero cell-
based vaccine production [14,15,16,17,18,19]. Several studies
have proved the feasibility of generating reassortant vaccine
viruses in Vero cells [7,19,20,21]. We are using the Vero-15 virus
as a master virus to generate reassortant viruses for other influenza
A subtypes and evaluate their growth efficiency in Vero cells.
It has been reported that antigen yields of engineered-H5N1
viruses in eggs are 30–40% lower than the average of seasonal
influenza vaccines [22]. Howard et al., found that recent wild-type
H5N1 viruses (A/Vietnam/1203/94 and A/Indonesia/05/2005)
grew to 0.2 to 1610
9 TCID50/ml in microcarrier-based Vero cell
culture systems [10], which is similar to the virus titers of our Vero
cell-adpated H5N1 reassortant virus but is much higher than those
of seasonal wild-type influenza viruses and egg-adapted vaccine
viruses [3]. In addition, these wild-type H5N1 viruses did not
change their antigenicity and HA sequences in the end of
production [10]. Moreover, this H5N1 vaccine candidate was
well-tolerated and highly immunogenic in humans and has been
licensed as a prepandemic vaccine in Europe [11,23]. The reasons
why the wild-type H5N1 viruses grow much efficiently than wild-
type H1N1 and H3N2 viruses are not clear, which need further
studies to elucidate.
The egg-adapted high-growth A/PR/8/1934 (PR8) virus strain
has been widely used as a master donor virus to generate vaccine
seed viruses for manufacturing egg-based inactivated influenza
vaccines [7,12]. One recent study showed that polymerase (PA/
PB1/PB2) and NS gene segments were related to high-growth
property in eggs of the PR8 virus [8]. In addition, high-growth
property in MDCK cells of PR8 virus was determined to be
related to single mutation at position 360 (SRY of PB2 protein
[24]. A previous study suggested that NS gene is related to
adaptation of the PR8 virus in Vero cells but molecular
determinants of high-growth influenza viruses in Vero cells have
not been well defined [19]. Our Vero-adapted influenza H5N1
virus has mutations on 4 gene segments including the S360Y
mutation of PB2 protein, compared with the original NIBRG-14
H5N1 vaccine virus. Identifying molecular determinants of high-
growth influenza viruses in Vero cells would be valuable for
establishing the platform of Vero cell-based influenza vaccine
production.
The current global manufacturing capacity of influenza vaccines
are concentrated in Australia, Europe and North America and will
not meet the urgent demand during an influenza pandemic, so
countries without manufacturing capacity may not be able to have
Table 3. Growth efficiency of Vero-adapted influenza H5N1
virus (Vero-15) in microcarrier-based Vero cell cultures in 100-
ml spinner flasks.
Virus titers
Days post infection HA units/50 mL TCID50/ml (log10)
2 ,4 3.8360.19
3 128 7.7160.10
4 1024 8.5860.07
5 1024 8.7860.10
6 2048 8.6060.00
HA: hemagglutination.
TCID50 (50% tissue culture infectious dose) was measured in triplicate and
shown as geometric mean 6 standard error of mean.
doi:10.1371/journal.pone.0024057.t003
Table 2. Genetic differences between the NIBRG-14 and Vero-adapted H5N1 (Vero-15) viruses.
Nucleotides changes Amino acid changes
Gene segments Position NIBRG-14 Vero-15 Position NIBRG-14 Vero-15
PB2 1077 c a 360* S Y
PB1 583 a t 195 K L
584 a t
1257 c t
1737 g a
PA 1482 a g 494 E G
NS 271 t c 90 L P
331 t c 110 L P
335 t c
*Based on numbering of A/PR/8/34 (accession no. CAA23855).
doi:10.1371/journal.pone.0024057.t002
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has developed a global pandemic influenza action plan to increase
vaccine supply. Building new production plants in both developing
and industrialized countries is one of the various strategiessuggested
in the WHO action plan [2]. Egg-based and cell-based culture
systems are two matured technologies for manufacturing influenza
and other viral vaccines. The egg-based technology has long history
of success on supplying seasonal influenza vaccines but it can not be
scaled-up in a short term and may not have egg supply during a
pandemic causing by highly pathogenic avian influenza viruses,
suchasH5N1viruses.Therefore, cell-based technology is becoming
an attractive option for new facilities. A novel influenza H1N1 virus
emerged in March 2009 in Central America and spread globally by
June 2009 [26,27]. Among the various tools to mitigate the impact
of a pandemic, vaccination is considered to be the most cost-
effective strategy. The urgent development of pandemic influenza
H1N1 vaccines raised complex challenges, especiallyat a time when
seasonal vaccine productions were ongoing. Therefore, pandemic
influenza H1N1 vaccines were not available until September 2009
and their supplies were far below the expected productivity [26,27].
Since Vero cell is the most popular continuous cell line for
manufacturing human vaccines and Vero cell banks fulfilling the
cGMP requirements are readily available in many vaccine
production facilities, WHO and national authorities may consider
preparing for the next influenza pandemic by generating Vero cell-
adapted high-growth vaccine viruses with pandemic potentials such
asinfluenzaH2N2,H5N1,H7N7 andH9N2 andconductingclinicl
trials of these Vero cell-derived panemic vaccine candidates. When
the next influenza pandemic occurs, all Vero cell culture facilities
can be conveted to manufacture pandemic influenza vaccines.
Thus, global productivity of pandemic influenza vaccines will be
increased promptly to meet the urgent demand during influenza
pandemics.
Materials and Methods
Adaptation of NIBRG-14 in Vero cells
The NIBRG-14 vaccine viruses were grown in eggs by the
NIBSC and supplied to Taiwan Centers for Disease Control
(CDC). Taiwan CDC further amplified the NIBRG-14 viruses in
eggs and supplied this to the Vaccine Research and Development
Center of National Health Research Institutes (NHRI), Taiwan.
Vero cells were purchased from the American Type Culture
Collection (ATCC, USA) and were grown in M199 medium
(GibcoBRL, USA) plus 10% FBS (Moregate, Australia) within
passage 135–150. The NIBRG-14 vaccine viruses were adapted
with 11 passages in Vero cells supplemented with 2 mg/ml TPCK-
trypsin (Sigma, USA) including 2 rounds of plaque purification in
6-well plates. The infectious virus research was conducted under
biosafety level 2+ approved by the NHRI Biosafety Office.
Virological assays
HA titrations were conducted in 96-well microplates using
turkey red blood cells (RBC) following the standard technique
[28]. Virus infectious titers were measured using the 50% tissue
culture infectious doses (TCID50) assay based on cytopathic effect
(CPE) and the plaque assay based on plaque forming unit (PFU) in
Vero cells [15,28]. A positive control with pre-specified acceptable
range was included for conducting HA, TCID50, and plaque
assays.
Determination of virus growth efficiency in Vero cells
Influenza H5N1 viruses were grown in T75 flasks supplemented
with TPCK-trypsin and supernatant was harvested at day 1–5 post
infection for measuring HA and infectious virus titers. For the
NIBRG-14 virus strain, multiplicity of infection (MOI) were 10
21,
10
22, and 10
23 TCID50/cells since the NIBRG-14 virus strain
can not cause significan CPE in a lower MOI. For the Vero-
adapted virus strain, MOI were 10
23, and 10
24 TCID50/cells.
Antigenicity test
To measure the antigenicity relatedness between NIBRG-14
and the Vero cell-adapted viruses, NIBRG-14 standard antisera
(NIBSC, UK) was used to measure antibody titers against NIBRG-
14 and Vero cell-adapted viruses using the standard hemagglu-
tinination inhibition (HI) assay [28].
Determination of virus nucleotide sequences
Virus RNA was extracted by a commercial kit (Geneaid,
Taoyuan, Taiwan). The extracted virus RNA was amplified using
the one-step RT-PCR (Promega, Madison,WI) for HA and NA or
two-step RT-PCR (Invitrogen, USA) for the other six gene
segments. Sequences of the oligonucleotide primers used in this
study are available upon request. The amplified DNA was
sequenced using the ABI 3730 XL DNA Analyzer (Applied
Biosystem Inc., Foster City, CA). Nucelotide sequences reported in
this study have been submitted to public domain (accession
no. GQ454861,GQ454868).
Cell and virus culture in microcarriers
Potential of using the Veo-adapted H5N1 viruses as a vaccine
seed virus was evaluated in a microcarrier-based cell culture
system using serum-containing medium. Cytodex 1 microcarriers
(GE Healthcare, USA) were hydrated, autoclaved, and precondi-
tioned according to manufacturer’s instruction. Growth curves of
Vero cells with different culture conditions were tested in 100-ml
spinner flasks (50 ml working volume) and microcarriers were
sampled to count cell density every day. When the cells grew
confluent on microcarriers, the H5N1 viruses were added to infect
cells cultured in M199 medium supplemented with TPCK-trypsin
[9].
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